Acambis welcomes sanofi pasteur's dengue vaccine progress
Advertisement
Acambis plc welcomes sanofi pasteur's reported progress with a dengue vaccine candidate based on technology licensed from Acambis. Sanofi pasteur, the vaccines division of the sanofi-aventis Group, has announced positive results from Phase 2 trials and plans to start a Phase 3 trial programme in 2008.
The trial results were announced at a Research & Development meeting held in Paris, by sanofi-aventis. During the meeting, dengue fever was highlighted as one of the most common tropical diseases and a growing public health concern. Worldwide, 50-100 million people are affected and cases are appearing in northern Australia and Texas. Sanofi pasteur also highlighted that the potential market for a dengue vaccine could be worth in excess of EUR1bn per annum.
Sanofi pasteur also highlighted that it plans to start a large-scale Phase 3 efficacy study in 2008, making this project the first tetravalent candidate dengue vaccine in the world to reach this stage of clinical development.
Other news from the department research and development
